Advertisement
Canada markets closed

  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • Bitcoin CAD

    83,212.08
    -3,413.77 (-3.94%)
     

  • CMC Crypto 200

    1,256.28
    -101.73 (-7.49%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     

  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS DOW POSTS 8TH STRAIGHT WIN

Fed's Michelle Bowman echoes higher-for-longer mantra for interest rates

Novartis suspends two cancer therapies over quality concerns

Reuters
·1 min read

ZURICH, May 5 (Reuters) - Novartis said on Thursday it had temporarily suspended the production of its Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing.

"Novartis is conducting a thorough review of the situation and currently expects to resolve the issues and resume some supply in the next six weeks", the Swiss company said.

The drugmaker added in a statement that some doses of cancer therapy Lutathera would be available in Europe and Asia from a site in Spain, but there might be some delays in supply.

Lutathera and Pluvicto are both so-called radioligand therapies, a type of treatment that uses nuclear medicine to precisely target and treat cancer cells. (Reporting by Silke Koltrowitz; Editing by Alexander Smith)